Published in Am J Pathol on March 01, 1998
FAK deficiency in cells contributing to the basal lamina results in cortical abnormalities resembling congenital muscular dystrophies. Neuron (2003) 2.86
Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci (2008) 1.66
Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest (1999) 1.64
Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun (2000) 1.63
Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J Leukoc Biol (2008) 1.25
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia (2003) 1.22
Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J Neurosci Res (2003) 1.15
Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am J Pathol (2006) 1.14
Borrelia spirochetes upregulate release and activation of matrix metalloproteinase gelatinase B (MMP-9) and collagenase 1 (MMP-1) in human cells. Infect Immun (2001) 1.13
Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol (2001) 1.12
Astrocytic tissue inhibitor of metalloproteinase-1 (TIMP-1) promotes oligodendrocyte differentiation and enhances CNS myelination. J Neurosci (2011) 1.11
Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. J Virol (2005) 1.10
A new role for TIMP-1 in modulating neurite outgrowth and morphology of cortical neurons. PLoS One (2009) 1.01
Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection. J Virol (2002) 1.00
Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol (2007) 1.00
Cleavage of myelin associated glycoprotein by matrix metalloproteinases. J Neuroimmunol (2007) 0.98
Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci (2015) 0.97
Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol (2002) 0.94
Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am J Pathol (2000) 0.92
Morbillivirus infection of the mouse central nervous system induces region-specific upregulation of MMPs and TIMPs correlated to inflammatory cytokine expression. J Virol (2001) 0.91
Astrocyte regulation of CNS inflammation and remyelination. Brain Sci (2013) 0.90
A dual role for microglia in promoting tissue inhibitor of metalloproteinase (TIMP) expression in glial cells in response to neuroinflammatory stimuli. J Neuroinflammation (2011) 0.90
MMP9 deficiency does not decrease blood-brain barrier disruption, but increases astrocyte MMP3 expression during viral encephalomyelitis. Glia (2011) 0.88
T-cell production of matrix metalloproteinases and inhibition of parasite clearance by TIMP-1 during chronic Toxoplasma infection in the brain. ASN Neuro (2011) 0.87
CCAAT/enhancer binding protein β expression is increased in the brain during HIV-1-infection and contributes to regulation of astrocyte tissue inhibitor of metalloproteinase-1. J Neurochem (2011) 0.87
Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. Biochem Res Int (2012) 0.87
Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1. Am J Pathol (2007) 0.86
Characterization of an in vitro rhesus macaque blood-brain barrier. J Neuroimmunol (2002) 0.86
Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study. BMC Neurosci (2005) 0.85
Regulation of endothelial nitric oxide synthase by agmatine after transient global cerebral ischemia in rat brain. Anat Cell Biol (2010) 0.85
Matrix metalloproteinase expression in the olfactory epithelium. Neuroreport (2003) 0.85
MMP-3 mediates psychosine-induced globoid cell formation: implications for leukodystrophy pathology. Glia (2013) 0.85
Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice. Am J Pathol (2010) 0.84
Immunohistochemical changes in vulnerable rat brain regions after reversible global brain ischaemia. J Mol Histol (2007) 0.84
Production and Roles of Glial Tissue Inhibitor of Metalloproteinases-1 in Human Immunodeficiency Virus-1-Associated Dementia Neuroinflammation: A Review. Am J Infect Dis (2009) 0.82
Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism. Neuroscience (2011) 0.81
Extracellular regulated kinase 1/2 signaling is a critical regulator of interleukin-1β-mediated astrocyte tissue inhibitor of metalloproteinase-1 expression. PLoS One (2013) 0.81
Immunohistochemical analysis of TIMP-2 and collagen types I and IV in experimental spinal cord ischemia-reperfusion injury in rats. J Spinal Cord Med (2011) 0.81
Matrix Metalloproteinases in Non-Neoplastic Disorders. Int J Mol Sci (2016) 0.81
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice. PLoS One (2012) 0.81
Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain (2014) 0.81
MMP-independent role of TIMP-1 at the blood brain barrier during viral encephalomyelitis. ASN Neuro (2013) 0.78
Low brain DHA content worsens sensorimotor outcomes after TBI and decreases TBI-induced Timp1 expression in juvenile rats. Prostaglandins Leukot Essent Fatty Acids (2013) 0.78
CNS infection, CSF matrix metalloproteinase concentrations, and clinical/laboratory features. Neurology (2011) 0.77
Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers. J Cereb Blood Flow Metab (2016) 0.77
Timp-3 deficiency impairs cognitive function in mice. Lab Invest (2009) 0.76
Synthetic prion Peptide 106-126 resulted in an increase matrix metalloproteinases and inflammatory cytokines from rat astrocytes and microglial cells. Toxicol Res (2012) 0.75
Matrix metalloproteinases contribute to the regulation of chemokine expression and pulmonary inflammation in Cryptococcus infection. Clin Exp Immunol (2015) 0.75
A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 9.31
The gene family encoding the mouse ribosomal protein L32 contains a uniquely expressed intron-containing gene and an unmutated processed gene. Cell (1984) 4.41
Biology and biochemistry of proteinases in tumor invasion. Physiol Rev (1993) 4.17
Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem (1989) 2.87
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A (1993) 2.79
Cooperative signaling by alpha 5 beta 1 and alpha 4 beta 1 integrins regulates metalloproteinase gene expression in fibroblasts adhering to fibronectin. J Cell Biol (1995) 2.45
A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature (1993) 2.33
Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett (1992) 2.21
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Role of cytokines and inflammatory mediators in tissue destruction. J Periodontal Res (1993) 2.12
Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A (1996) 2.12
The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med (1995) 2.08
Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem (1994) 1.99
Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci (1994) 1.86
Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest (1994) 1.82
The family of matrix metalloproteinases. Ann N Y Acad Sci (1994) 1.81
Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res (1995) 1.63
Molecular cloning, chromosomal localization, and bacterial expression of a murine macrophage metalloelastase. J Biol Chem (1992) 1.57
Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol (1996) 1.55
Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett (1995) 1.54
Dual regulation of IL-1 beta-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-kappa B and AP-1. Am J Physiol (1996) 1.42
Regulation of matrix metalloproteinase activity. Ann N Y Acad Sci (1994) 1.39
Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Commun (1996) 1.38
Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett (1997) 1.36
Cytokine and chemokine regulation of proMMP-9 and TIMP-1 production by human peripheral blood lymphocytes. J Immunol (1997) 1.32
Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol (1996) 1.31
Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med (1994) 1.28
Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res (1993) 1.25
Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem (1995) 1.23
Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol (1992) 1.22
Structural organization and chromosomal localization of the mouse collagenase type I gene. Biochem J (1995) 1.22
TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res (1992) 1.21
Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation (1997) 1.20
Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg (1994) 1.19
The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol (1996) 1.18
Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol (1997) 1.14
Components of the nuclear signaling cascade that regulate collagenase gene expression in response to integrin-derived signals. J Cell Biol (1995) 1.11
Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol (1994) 1.11
Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene (1996) 1.08
Indictment of the microglia as the villain in multiple sclerosis. Neurology (1997) 1.08
Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J Immunol (1995) 1.07
Identification of a serum- and phorbol ester-responsive element in the murine tissue inhibitor of metalloproteinase gene. J Biol Chem (1991) 1.06
Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis (1995) 1.05
Interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. Immunol Today (1996) 1.03
Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res (1995) 1.02
Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry (1997) 1.00
RNAse protection assays for the simultaneous and semiquantitative analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. J Immunol Methods (1997) 0.98
White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathol (1995) 0.97
Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett (1990) 0.96
TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res (1996) 0.94
Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest (1996) 0.92
Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid. Curr Eye Res (1997) 0.92
The immune response to myelin proteolipid protein in the Lewis rat: identification of the immunodominant B cell epitope. J Neuroimmunol (1990) 0.92
Enhanced detection of casein zymography of matrix metalloproteinases. Anal Biochem (1995) 0.90
Relaxed specificity of matrix metalloproteinases (MMPS) and TIMP insensitivity of tumor necrosis factor-alpha (TNF-alpha) production suggest the major TNF-alpha converting enzyme is not an MMP. Biochem Biophys Res Commun (1996) 0.90
MMP-9 (gelatinase B) mRNA is expressed during mouse neurogenesis and may be associated with vascularization. Brain Res Dev Brain Res (1995) 0.90
Simultaneous analysis of multiple cytokine receptor mRNAs by RNase protection assay in LPS-induced endotoxemia. Lymphokine Cytokine Res (1994) 0.85
Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J Neuropathol Exp Neurol (1995) 0.85
Cytokine-induced endogenous procollagenase stored in the extracellular matrix of soft connective tissue results in a burst of collagen breakdown following its activation. J Periodontal Res (1996) 0.81
Localization of proteinase expression in the developing rabbit brain. Brain Res Dev Brain Res (1995) 0.77
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 9.70
Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 8.19
Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J (2003) 6.23
Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest (2000) 4.90
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest (2000) 4.16
Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med (1998) 4.04
Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A (1996) 2.93
Ciliogenesis and left-right axis defects in forkhead factor HFH-4-null mice. Am J Respir Cell Mol Biol (2000) 2.90
Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. Proc Natl Acad Sci U S A (1999) 2.80
K-ras activation generates an inflammatory response in lung tumors. Oncogene (2006) 2.78
Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem (1991) 2.71
Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ Res (2000) 2.66
The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell (2000) 2.49
Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic beta cells. Nature (1988) 2.46
Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest (1998) 2.43
Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med (2000) 2.36
Mechanical ventilation with or without 7-day circuit changes. A randomized controlled trial. Ann Intern Med (1995) 2.26
Matrix metalloproteinases in lung biology. Respir Res (2000) 2.18
A randomized, controlled trial of protocol-directed versus physician-directed weaning from mechanical ventilation. Crit Care Med (1997) 2.18
A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J Virol (2000) 2.04
Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem (1997) 2.00
Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. Science (2000) 1.97
Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A (1996) 1.92
Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol (1998) 1.87
Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol (1998) 1.87
Dynamic regulation of alpha- and beta-chemokine expression in the central nervous system during mouse hepatitis virus-induced demyelinating disease. J Immunol (1998) 1.83
Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med (2001) 1.81
Chemokine gene expression in the brains of mice with lymphocytic choriomeningitis. J Virol (1997) 1.79
The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J (2003) 1.75
Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci (1999) 1.73
Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum. Neuropathol Appl Neurobiol (2010) 1.65
Elastin degradation by matrix metalloproteinases. Cleavage site specificity and mechanisms of elastolysis. J Biol Chem (1997) 1.62
Normal neutrophil function in cathepsin G-deficient mice. Blood (1999) 1.53
The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats. J Biol Chem (1996) 1.53
Chronic obstructive pulmonary disease * 3: Experimental animal models of pulmonary emphysema. Thorax (2002) 1.51
Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res (2005) 1.50
Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am J Pathol (1998) 1.48
Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol (1998) 1.46
Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci U S A (1997) 1.46
End-stage chronic obstructive pulmonary disease: the cigarette is burned out but inflammation rages on. Am J Respir Crit Care Med (2001) 1.45
Fibrillin degradation by matrix metalloproteinases: implications for connective tissue remodelling. Biochem J (1999) 1.45
Deletions of the long arm of chromosome 10. Am J Med Genet (1985) 1.44
Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J Virol (2001) 1.35
Developmental expression of latent transforming growth factor beta binding protein 2 and its requirement early in mouse development. Mol Cell Biol (2000) 1.34
Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Immunol (1991) 1.34
DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol (1998) 1.34
Intraoral findings and anomalies in neonates. Pediatrics (1982) 1.32
Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol (1999) 1.31
Human macrophage metalloelastase. Genomic organization, chromosomal location, gene linkage, and tissue-specific expression. J Biol Chem (1995) 1.30
A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest (2000) 1.30
Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem (2000) 1.29
The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry (2001) 1.25
Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol (1995) 1.24
Patient transport from intensive care increases the risk of developing ventilator-associated pneumonia. Chest (1997) 1.23
Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys (1995) 1.20
Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation. J Neurosci Res (1999) 1.16
Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev Neurosci (1994) 1.16
Neurofibromatosis: oral and radiographic manifestations. Oral Surg Oral Med Oral Pathol (1984) 1.15
Enhanced expression of human metalloelastase (MMP-12) in cutaneous granulomas and macrophage migration. J Invest Dermatol (1999) 1.12
Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry (2007) 1.12
Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases. J Biol Chem (2000) 1.08
Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am J Pathol (1998) 1.07
Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Lett (1995) 1.06
Transgenic expression of TNF by astrocytes increases mechanical allodynia in a mouse neuropathy model. Neuroreport (2000) 1.06
Interferon-gamma enhances the expression of the major histocompatibility class I antigens on mouse pancreatic beta cells. Diabetes (1985) 1.06
Prospective study of long-term pulmonary manifestations of mantle irradiation. Int J Radiat Oncol Biol Phys (1990) 1.05
Expression of alpha/beta interferons (IFN-alpha/beta) and their relationship to IFN-alpha/beta-induced genes in lymphocytic choriomeningitis. J Virol (1994) 1.05
Deletion 2q: two new cases with karyotypes 46,XY,del(2)(q31q33) and 46,XX,del(2)(q36). J Med Genet (1983) 1.05
Chemokines and the inflammatory response to viral infection in the central nervous system with a focus on lymphocytic choriomeningitis virus. J Neurovirol (1999) 1.04
Lipopolysaccharide-induced IL-12 expression in the central nervous system and cultured astrocytes and microglia. J Immunol (1997) 1.02
Experimental autoimmune encephalomyelitis on the SJL mouse: effect of gamma delta T cell depletion on chemokine and chemokine receptor expression in the central nervous system. J Immunol (2000) 1.02
Expression of human macrophage metalloelastase (MMP-12) by tumor cells in skin cancer. J Invest Dermatol (2000) 1.01
Tricho-dento-osseous syndrome: heterogeneity or clinical variability. Am J Med Genet (1983) 1.01
Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry (1997) 1.00
Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis. J Immunol (2000) 1.00
C10 is a novel chemokine expressed in experimental inflammatory demyelinating disorders that promotes recruitment of macrophages to the central nervous system. Am J Pathol (1999) 0.99
RNAse protection assays for the simultaneous and semiquantitative analysis of multiple murine matrix metalloproteinase (MMP) and MMP inhibitor mRNAs. J Immunol Methods (1997) 0.98
Effects of adenosine, 2-deoxyadenosine and N6-phenylisopropyladenosine on rat islet function and metabolism. Biochem J (1982) 0.98
Polymorphic variation in surfactant protein B is associated with COPD exacerbations. Eur Respir J (2008) 0.98
Expression of nitric oxide synthase (NOS)-2 following permanent focal ischemia and the role of nitric oxide in infarct generation in male, female and NOS-2 gene-deficient mice. Brain Res (1999) 0.97
Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J Immunol (1999) 0.97
A randomized clinical trial comparing an extended-use hygroscopic condenser humidifier with heated-water humidification in mechanically ventilated patients. Chest (1998) 0.96
Astrocyte-targeted expression of IFN-alpha1 protects mice from acute ocular herpes simplex virus type 1 infection. J Immunol (1998) 0.96
Molecular cloning, chromosomal location, and tissue-specific expression of the murine cathepsin G gene. Blood (1993) 0.95
Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. J Immunol (1999) 0.95
Monocyte inflammation augments acrolein-induced Muc5ac expression in mouse lung. Am J Physiol (1999) 0.95
In vitro techniques for the assessment of neurotoxicity. Environ Health Perspect (1998) 0.95
Barrier disruption increases gene expression of cytokines and the 55 kD TNF receptor in murine skin. Exp Dermatol (1997) 0.95
Clinical heterogeneity in the tricho-dento-osseous syndrome. Hum Genet (1983) 0.94
Heterogeneity in genetic disorders that affect the orofacies. Birth Defects Orig Artic Ser (1983) 0.93
Cytokines and chemokines as mediators of protection and injury in the central nervous system assessed in transgenic mice. Curr Top Microbiol Immunol (2002) 0.93
Efficacy of and patient preference for three counseling formats. J Craniofac Genet Dev Biol (1986) 0.93
Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest (1996) 0.92